Summary
Other Scenarios:
- ACAM - PFE
- ACAM - JNJ
- PFE - MRX
- JNJ - MRX
| Buyer: | Acambis plc (ADR) (ACAM) | Last Price: | 7.21 | Market Cap.: | 3.87B |
|---|---|---|---|---|---|
| Target: | Medicis Pharmaceutical Corporation (MRX) | Last Price: | 28.93 | Market Cap.: | 1.57B |
Lines of Business Summary:
- Acambis plc (ADR) (ACAM) competes in 1 industry and 6 product/service groups
- Medicis Pharmaceutical Corporation (MRX) competes in 1 industry and 23 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- Acambis plc (ADR) (ACAM) has 1 and Medicis Pharmaceutical Corporation (MRX) has 2 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
*Healthcare |
|
|
860 |
Biopharmaceuticals |
|
|
311 |
|
Medical Devices |
|
246 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 9)
|
Target (Total: 18)
|
Buyern/a |
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 2)
|
Target (Total: 6)
|
Buyer (Total: 1)
|
Target (Total: 5)
|
Key Financial Summary:
| Metric | Buyer | Target |
|---|---|---|
| Number of Employees | 270 | 359 |
| Revenue Per Employee | 117,943.6 | 927,697.2 |
| Total Revenue | 8.0 | 83.3 |
| Total Expenses | 26.8 | 64.9 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
9.4 | 12.0 |
|
SG&A Expense
|
2.4 | 41.5 |
|
Research & Development
|
15.0 | 5.1 |
|
Other Operating Expense
|
0.0 | 0.0 |
|
Operating Income
|
-18.8 | 18.4 |
|
Unusual Income
|
0.0 | 0.0 |
|
Gross Margin %
|
-17.39 | 85.56 |
| Metric | Buyer | Target |
|---|---|---|
|
Operating Margin %
|
-234.78 | 22.09 |
| Total Assets | 229.6 | 1,053.9 |
| Return on Equity % | -49.33 | 9.86 |
|
Cash+ ST Inv. Per Share
|
2.39 | 9 |
| Total Debt | 8.7 | 453.1 |
|
Curr Portion of LTD/Cap Lease
|
0.0 | 0.0 |
| Total Debt to Equity | 5.56 | 89.6 |
|
LT Debt to Capital
|
5.26 | 47.26 |
|
Fwd P/E
|
n/a | 21.80 |
|
Fwd P/Rev
|
n/a | 4.15 |
| Book Value | 156.6 | 505.6 |
Individual Company Summary
Focused
Buyer
Focused ():
*Healthcare > Biopharmaceuticals > Infectious Diseases > Viral > Vaccines
Target
Focused ():
*Healthcare > Biopharmaceuticals > Dermatology
Business Description
Buyer
Acambis plc is a biopharmaceutical company operating in the infectious disease arena, with a focus on developing new vaccines. The Company's revenues are principally derived by sales of ACAM2000, the investigational product in its smallpox vaccine franchise, which is being sold to governments, even while it undergoes clinical testing. In addition, revenues also come from sales in North America of an oral typhoid vaccine, Vivotif by its sales and distribution operation, Berna Products Corporation. The majority of Acambis' operations are in the United States, with research and development in Cambridge, Massachusetts; manufacturing in Canton, Massachusetts; a sales and marketing operation in Miami, Florida, and a lyophilisation and fill and finish facility in Rockville, Maryland that the Company acquired in May 2005. During the year ended December 31, 2004, Acambis' customer, the United States Centres for Disease Control and Prevention, accounted for 84% of its revenues.
Target
Medicis Pharmaceutical Corporation (Medicis) is an independent specialty pharmaceutical company focusing primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing of products in the United States for the treatment of dermatologic, aesthetic and podiatric conditions in the United States and Canada. The Company offers a range of products addressing various conditions, including acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, eczema, skin and skin-structure infections, seborrheic dermatitis and cosmesis (improvement in the texture and appearance of skin). Medicis offers 15 branded products, including DYNACIN (minocycline HCI), LOPROX (ciclopirox), OMNICEF (cefdinir), PLEXION (sodium sulfacetamide/sulfur), RESTYLANE (hyaluronic acid), TRIAZ (benzoyl peroxide) and VANOS (fluocinonide) Cream 0.1%. On March 20, 2005, the Company entered into an agreement and plan of merger with Inamed Corporation.
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Medical Devices |
|
|
|
Plastic/Reconstructive Surgery
The Plastic/Reconstructive Surgery Subsector includes medical devices that treat and modify a patient's external appearance.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Dermatology |
|
|
Acne |
|
|
|
Rosacea |
|
|
|
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat chronic inflammatory disorder of the face characterized by redness and pimple formation by inhibiting bacterial folic acid synthesis.
Target Products:
|
|
|
|
Vulgaris |
|
|
|
Antibacterial Agents |
|
|
|
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Target Products:
|
|
|
|
Keratolytic Agents
Therapeutics that soften, separate, and cause the shedding of skin.
Target Products:
|
|
|
|
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.
Target Products:
|
|
|
|
Aging Disorders |
|
|
|
Photoaging |
|
|
|
Enzymatic Oxidation Inhibitors
Therapeutics composed of plant hormones that treat the effects on the skin of aging and sun exposure.
Target Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Dermatitis |
|
|
|
Atopic (Eczema) |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat atopic dermatoses by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Target Products:
|
|
|
|
Seborrheic (Dandruff) |
|
|
|
Antifungal Agents |
|
|
|
Imidazoles
Therapeutics that treat and prevent skin diseases caused by fungi.
Target Products:
|
|
|
|
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.
Target Products:
|
|
|
|
Dermatoses |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Target Products:
|
|
|
|
Pruritus |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Target Products:
|
|
|
|
Psoriasis |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Target Products:
|
|
|
|
Pigmentation Disorders |
|
|
|
Hyperpigmentation |
|
|
|
Enzymatic Oxidation Inhibitors
Therapeutics that treat disorders characterized by darkening of the skin by inhibiting metabolic processes of pigment producing skin cells.
Target Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Urea Cycle Disorders |
|
|
|
Glutamine Acetylyzing Agents
Therapeutics that conjugate with glutamine to help excrete nitrogen waste.
Target Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Psoriasis |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, causing the shedding of the horny layer of the skin with a steroidal compound.
Target Products:
|
|
|
|
Infectious Diseases |
|
|
|
Arachnids |
|
|
|
Lice |
|
|
|
Cholinesterase Inhibitors
Therapeutics that treat Lice by inhibiting the break down of acetylcholine.
Target Products:
|
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Target Products:
|
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Target Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial |
|
|
|
Single Target |
|
|
|
Typhoid Fever
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause typhoid fever.
Buyer Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Tinea Corporis (Ringworm) |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Tinea Cruris (Jock Itch) |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the groin and perineum by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Tinea Pedis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Tinea Versicolor |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Viral |
|
|
|
Vaccines |
|
|
|
Viral |
|
|
|
Single Target |
|
|
|
Japanese Encephalitis
Therapeutics that prevent or treat viral infections characterized by inflammation of the brain by producing or artificially increasing immunity to the Japanese B Encephalitis virus.
Buyer Products:
|
|
|
|
Variola (Smallpox)
Therapeutics that prevent or treat viral infections that cause a diffuse and extensive distribution of lesions by producing or artificially increasing immunity to the Variola virus.
Buyer Products:
|
|
|
|
Yellow Fever
Therapeutics that prevent or treat viral infections characterized by fever and hemorrhage by producing or artificially increasing immunity to the yellow fever virus.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Medical Devices |
|
|
|
Plastic/Reconstructive Surgery |
|
|
|
Treatment |
|
|
|
Wrinkle Removal |
|
|
|
Hyaluronic Acid |
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
GlaxoSmithKline plc (ADR)
|
|
n/a | 158,330.716 | 19.29 | 18.56 | 4.17 | 4.17 | 28.38 | |
|
sanofi-aventis (ADR)
|
|
n/a | 117,145.313 | n/a | 11.83 | 4.03 | 3.33 | n/a | |
|
Wyeth
|
|
n/a | 65,725.563 | 17.91 | 16.16 | 3.50 | 3.26 | 8.34 | |
| Buyer | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 158,330.716 | 19.29 | 18.56 | 4.17 | 4.17 | 28.38 | |
|
sanofi-aventis (ADR)
|
|
n/a | 117,145.313 | n/a | 11.83 | 4.03 | 3.33 | n/a | |
| Target | |||||||||
|
Pfizer Inc.
|
|
n/a | 191,895.175 | 23.84 | 13.03 | 3.74 | 3.73 | 13.64 | |
|
Johnson & Johnson
|
|
n/a | 175,639.871 | 16.93 | 15.76 | 3.48 | 3.26 | n/a | |
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 158,330.716 | 19.29 | 18.56 | 4.17 | 4.17 | 28.38 | |
|
sanofi-aventis (ADR)
|
|
n/a | 117,145.313 | n/a | 11.83 | 4.03 | 3.33 | n/a | |
|
Wyeth
|
|
n/a | 65,725.563 | 17.91 | 16.16 | 3.50 | 3.26 | 8.34 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 44,823.896 | 14.94 | 18.92 | 2.33 | 2.30 | n/a | |
|
Schering-Plough Corp.
|
|
n/a | 26,704.540 | 145.95 | 33.33 | 2.81 | 2.66 | 3.92 | |
|
Allergan, Inc.
|
|
n/a | 15,629.905 | 38.18 | 31.61 | 6.74 | 6.20 | 11.02 | |
|
Schering AG (ADR)
|
|
n/a | 15,142.999 | 21.29 | 18.60 | 2.47 | n/a | 4.96 | |
|
Altana AG (ADR)
|
|
n/a | 7,603.028 | 14.64 | 14.39 | 2.01 | n/a | 3.81 | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 6,243.654 | n/a | -18.68 | 12.73 | 10.82 | -9.48 | |
|
King Pharmaceuticals
|
|
n/a | 4,342.917 | 37.03 | 12.87 | 2.45 | 2.44 | 4.91 | |
|
Inamed Corporation
|
|
n/a | 3,362.007 | 48.80 | 40.30 | 7.84 | 7.49 | 10.66 | |
|
Mentor Corporation
|
|
n/a | 2,038.260 | 33.51 | 30.11 | 4.06 | 3.94 | 10.19 | |
|
Valeant Pharmaceuticals International
|
|
n/a | 1,806.932 | n/a | 69.75 | 2.20 | 1.97 | n/a | |
|
First Horizon Pharmaceutical Corp.
|
|
n/a | 736.904 | 17.86 | 17.69 | 3.41 | 2.64 | 30.28 | |
|
Taro Pharmaceutical Industries Ltd.
|
|
n/a | 412.506 | 23.80 | 25.36 | 1.36 | 1.35 | 1.07 | |
|
Bradley Pharmaceuticals, Inc.
|
|
n/a | 237.185 | 26.33 | 7.67 | 2.45 | 1.52 | -9.93 | |
|
Barrier Therapeutics, Inc.
|
|
n/a | 223.109 | n/a | -4.56 | 87.81 | 17.79 | n/a | |
|
Isolagen, Inc.
|
|
n/a | 72.625 | n/a | -2.05 | 8.22 | 7.64 | 40.64 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Baxter International Inc.
|
|
n/a | 24,830.452 | 25.75 | 18.74 | 2.52 | 2.41 | 11.02 | |
|
Cangene Corporation
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
sanofi-aventis (ADR)
|
|
n/a | 117,145.313 | n/a | 11.83 | 4.03 | 3.33 | n/a | |
|
Par Pharmaceutical Companies, Inc
|
|
n/a | 953.724 | n/a | 20.26 | 2.20 | 1.55 | 2.86 | |
|
Q-Med, Inc.
|
|
n/a | 167.100 | 43.01 | 41.08 | 7.55 | 4.14 | 6.67 | |
|
DPT Laboratories, Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Contract Pharmaceuticals Limited
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Patheon Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Federal Government Agencies (United States)
|
|
84.00% | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
McKesson Corporation
|
|
51.20% | 16,494.123 | 20.57 | 22.56 | 0.19 | 0.18 | 4.17 | |
|
Cardinal Health, Inc.
|
|
21.80% | 30,604.114 | 26.61 | 23.09 | 0.39 | 0.37 | 8.34 | |
|
AmerisourceBergen Corp.
|
|
n/a | 9,564.722 | 31.53 | 22.55 | 0.17 | 0.17 | 5.14 | |
|
BioMarin Pharmaceutical
|
|
n/a | 928.042 | n/a | -20.31 | 30.84 | 16.49 | -9.08 | |
|
Quality King Distributors
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
sanofi-aventis (ADR)
|
|
n/a | 117,145.313 | n/a | 11.83 | 4.03 | 3.33 | n/a | |
| Buyer | |||||||||
|
sanofi-aventis (ADR)
|
|
n/a | 117,145.313 | n/a | 11.83 | 4.03 | 3.33 | n/a | |
|
Baxter International Inc.
|
|
n/a | 24,830.452 | 25.75 | 18.74 | 2.52 | 2.41 | 11.02 | |
|
Chiron Corporation
|
|
n/a | 8,548.136 | 45.11 | 24.20 | 4.45 | 3.95 | 2.86 | |
|
Cangene Corporation
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Berna Biotech AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
sanofi-aventis (ADR)
|
|
n/a | 117,145.313 | n/a | 11.83 | 4.03 | 3.33 | n/a | |
|
Abbott Laboratories
|
|
n/a | 67,576.455 | 20.20 | 16.94 | 3.03 | 3.03 | 15.17 | |
|
Cardinal Health, Inc.
|
|
n/a | 30,604.114 | 26.61 | 23.09 | 0.39 | 0.37 | 8.34 | |
|
McKesson Corporation
|
|
n/a | 16,494.123 | 20.57 | 22.56 | 0.19 | 0.18 | 4.17 | |
|
AmerisourceBergen Corp.
|
|
n/a | 9,564.722 | 31.53 | 22.55 | 0.17 | 0.17 | 5.14 | |
|
Par Pharmaceutical Companies, Inc
|
|
n/a | 953.724 | n/a | 20.26 | 2.20 | 1.55 | 2.86 | |
|
BioMarin Pharmaceutical
|
|
n/a | 928.042 | n/a | -20.31 | 30.84 | 16.49 | -9.08 | |
|
Taro Pharmaceutical Industries Ltd.
|
|
n/a | 412.506 | 23.80 | 25.36 | 1.36 | 1.35 | 1.07 | |
|
Q-Med, Inc.
|
|
n/a | 167.100 | 43.01 | 41.08 | 7.55 | 4.14 | 6.67 | |
|
DPT Laboratories, Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Contract Pharmaceuticals Limited
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Dow Pharmaceutical Sciences, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Patheon Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Quality King Distributors
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 69.8 | 371.3 | 441.1 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 69.8 | 371.3 | 441.1 |
|
Cost of Revenue
|
43.7 | 53.6 | 97.3 |
|
SG&A Expense
|
11.3 | 144.5 | 155.8 |
|
Depreciation & Amortization
|
0.0 | 23.6 | 23.6 |
|
Research & Development
|
53.4 | 34.2 | 87.7 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
0.0 | 0.0 | 0.0 |
| Total Expenses | 108.4 | 255.9 | 364.4 |
|
Operating Income
|
-38.6 | 115.4 | 76.8 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
0.9 | 2.4 | 3.3 |
|
Other, Net
|
0.0 | 0.0 | 0.0 |
| Income Before Taxes | -32.4 | 117.8 | 85.5 |
| Income Taxes | -5.6 | 41.4 | 35.8 |
| Income After Taxes | -26.8 | 76.4 | 49.6 |
|
Net Income - Excl. Xord. Items
|
-26.8 | 76.4 | 49.6 |
|
Net Income - Incl. Xord. Items
|
-26.8 | 76.4 | 49.6 |
|
Income Avail. to Common
|
-26.8 | 76.4 | 49.6 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
53.6 | 54.3 | 107.9 |
|
Basic EPS - Excl. Xord. Items
|
-0.25 | 1.40 | 0.46 |
|
Basic EPS - Incl. Xord. Items
|
-0.50 | 1.40 | 0.46 |
| Full Dilution Adjustment | 0.0 | 1.7 | 1.7 |
| Fully Diluted Shares Outstanding | 53.6 | 69.8 | 123.5 |
|
F.D. EPS - Excl. Xord. Items
|
-0.52 | 1.19 | 0.40 |
|
F.D. EPS - Incl. Xord. Items
|
-0.52 | 1.19 | 0.40 |
| Dividends Per Common Share | 0.00 | 0.12 | 0.12 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
103.6 | 250.3 | 353.9 |
|
ST Investments
|
24.4 | 378.1 | 402.4 |
|
Accounts Receivable
|
24.9 | 43.3 | 68.2 |
|
Inventory
|
6.4 | 19.7 | 26.1 |
|
Other Current Assets
|
0.0 | 21.6 | 21.6 |
|
Current Assets
|
159.3 | 713.0 | 872.3 |
|
Accum D&A
|
0.0 | 0.0 | 0.0 |
|
PPE, Net
|
36.2 | 5.8 | 42.0 |
| Goodwill & Intangibles | 34.1 | 318.9 | 353.0 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
0.0 | 16.2 | 16.2 |
| Total Assets | 229.6 | 1,053.9 | 1,283.5 |
| Liabilities | |||
| Accounts Payable | 60.0 | 26.6 | 86.7 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 0.0 | 26.1 | 26.1 |
|
ST Debt
|
0.0 | 0.0 | 0.0 |
| Other (Current) Liabilities | 0.0 | 34.9 | 34.9 |
|
Current Liab.
|
60.0 | 87.6 | 147.7 |
|
LT Debt
|
8.7 | 453.1 | 461.8 |
|
Total LT Debt
|
8.7 | 453.1 | 461.8 |
| Deferred Taxes | 2.8 | 7.6 | 10.4 |
|
Other LT Liab.
|
1.4 | 0.0 | 1.4 |
|
Total Liabilities
|
72.9 | 548.3 | 621.2 |
| Shareholders Equity | |||
| Common Stock | 18.6 | 0.9 | 19.6 |
| Additional Paid in Capital | 170.6 | 548.1 | 718.6 |
| Retained Earnings | -32.5 | 299.3 | 266.7 |
| Treasure Stock | 0.0 | -342.7 | -342.7 |
| Other Equity | 0.0 | 0.1 | 0.1 |
|
Total Equity
|
156.6 | 505.6 | 662.3 |
|
Total Liab. & Equity
|
229.6 | 1,053.9 | 1,283.5 |
|
Shares Outstanding
|
53.6 | 54.4 | 108.0 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | -32.4 | 76.4 | 44.1 |
| CF Depreciation | 7.5 | 25.8 | 33.3 |
| CF Deferred Taxes | 0.0 | 15.7 | 15.7 |
| Other Non-Cash Items | 1.0 | 5.7 | 6.7 |
| Change in Working Capital | -40.2 | 20.5 | -19.7 |
| Total Cash From Operating Activities | -64.1 | 144.1 | 80.1 |
| Investing Cash Flow | |||
| Capital Expenditures | -7.1 | -5.3 | -12.5 |
| Other Investing Cash Flows | -2.8 | 95.0 | 92.3 |
| Total Cash From Investing Activities | -9.9 | 89.7 | 79.8 |
| Financing Cash Flow | |||
| Dividends Paid | 0.0 | -6.6 | -6.6 |
| Purchase Or Sale of Stock | 2.3 | -75.7 | -73.4 |
| Purchase and Retirement of Debt | 118.2 | 0.0 | 118.2 |
| Other Financing Cash Flow | -45.1 | 0.1 | -45.0 |
| Total Cash From Financing Activities | 69.6 | -82.2 | -12.6 |
| Exchange Rate Effects | 0.0 | 0.2 | 0.2 |
| Net Change in Cash | -4.4 | 151.9 | 147.6 |
| Cash Taxes Paid | 9.9 | 13.9 | 23.8 |
| Cash Interest Paid | 6.8 | 0.0 | 6.8 |